Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation
Xiaoyun Wang,Yuwei Bai,Bei Wang
DOI: https://doi.org/10.2147/jir.s453509
IF: 4.5
2024-03-19
Journal of Inflammation Research
Abstract:Xiaoyun Wang, 1, 2 Yuwei Bai, 1, 2 Bei Wang 1, 2 1 Institute of Integration of Traditional Chinese and Western Medicine, The Hospital Affiliated to Jiangnan University, Wuxi, People's Republic of China; 2 Wuxi School of Medicine, Jiangnan University, Wuxi, People's Republic of China Correspondence: Bei Wang, Email Background: Cancer represents a widespread global health challenge impacting millions of individuals worldwide. Identifying new targets for cancer treatment is a crucial step in developing more effective therapies. Among these potential targets, Coactosin-like protein 1 (COTL1), a cytoskeleton-associated protein with critical roles in cell migration, adhesion, and signaling, has shown involvement in tumor progression. Methods: GSCA, TIMER, SangerBox database were used to explore the COTL1 expression across different tumor types. We employed the TCGA Pan-Atlas Cancer Genomics Dataset, which is available through the cBioportal platform, to explore genetic alterations in COTL1. We conduct a comprehensive analysis of COTL1, encompassing gene expression, clinical prognosis, RNA modification, immunotherapy, and cancer stemness through SangerBox database. Clinical samples were validated using immunohistochemistry. Results: Our analysis revealed that COTL1 is highly expressed in most cancers and correlates with decreased survival in Glioma, Glioblastoma multiforme, and pan-kidney cohorts. Furthermore, COTL1 was found to be associated with DNA and RNA stemness in 20 and 22 different tumor types, respectively. Additionally, COTL1 showed positive correlations with immunological checkpoints and immune infiltration cells. It was also linked to tumor mutation burden (TMB), microsatellite instability (MSI), neoantigen (NEO), and programmed death ligand 1 (PD-L1), all of which are potential targets for immunotherapies. Moreover, a favorable relationship was demonstrated between genomic-instability markers such as heterozygosity (LOH), homologous recombination deficiency (HRD), and mutant allele tumor heterogeneity (MATH) with COTL1. Furthermore, our findings confirmed a positive correlation between COTL1 expression, CD8, and PD-L1 in LGG, as well as an association of high COTL1 expression with decreased patient survival in LGG. Conclusion: Based on these compelling findings, COTL1 may hold significant clinical implications for the development of novel cancer therapies and serve as a potential target for tumors associated with immunotherapy in the future. Keywords: COTL1, pan-cancer analysis, cancer therapy, prognosis biomarker, immune cell infiltration Cancer poses a formidable challenge to global health, causing substantial morbidity and mortality and placing a heavy burden on society. 1 Current cancer treatment approaches encompass a wide range, from surgery, chemotherapy, and radiotherapy to targeted therapy and immunotherapy. Despite some successes, patient prognosis remains suboptimal, with drug resistance, adverse effects, and other complications contributing to poor outcomes. 2 To address these challenges, there is an urgent need to identify new therapeutic targets and sensitive tumor biomarkers for improved cancer diagnosis and management. Such efforts are crucial for advancing our understanding of this complex disease and enhancing patient outcomes. COTL1 is a small cytoplasmic actin-binding protein 3–5 belonging to the ADF/cofilin family, critical for regulating actin dynamics and cytoskeleton organization. 6–8 COTL1 is implicated in various cellular processes like cell migration, adhesion, and signaling, and recent studies suggest its involvement in cancer progression. Upregulation of COTL1 has been observed in several cancer types, including breast, lung, and pancreatic cancer, and has been associated with poor prognosis and increased metastasis in some cases. 9–13 However, the precise mechanisms underlying COTL1's contribution to cancer progression are not yet fully understood. This study aims to investigate the potential association of COTL1 with cancer progression and development through pan-cancer analysis. The study also explores COTL1's role in immunotherapy and its involvement in cancer epigenetics and stemness. The findings of this study may offer valuable insights into potential therapeutic targets for cancer treatment, contributing to the existing knowledge base and underscoring the importance of COTL1 in cancer biology. These findings may have significant clinical implications for the development of novel cancer therapies and provide important information for further exploration of COTL1's role in cancer progression and development. To evaluate the expression of COTL1 in vario -Abstract Truncated-
immunology